118 related articles for article (PubMed ID: 35213517)
1. Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms.
McClung MR; Kagan R; Graham S; Bernick B; Mirkin S; Constantine G
Menopause; 2022 Feb; 29(3):304-308. PubMed ID: 35213517
[TBL] [Abstract][Full Text] [Related]
2. 17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial.
Kaunitz AM; Bitner D; Constantine GD; Bernick B; Graham S; Mirkin S
Menopause; 2020 Dec; 27(12):1382-1387. PubMed ID: 32740481
[TBL] [Abstract][Full Text] [Related]
3. Oral 17β-estradiol/progesterone (TX-001HR) and quality of life in postmenopausal women with vasomotor symptoms.
Simon JA; Kaunitz AM; Kroll R; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):506-512. PubMed ID: 30489424
[TBL] [Abstract][Full Text] [Related]
4. TX-001HR is associated with a clinically meaningful effect on severity of moderate to severe vasomotor symptoms in the REPLENISH trial.
Constantine GD; Simon JA; Kaunitz AM; Pickar JH; Revicki DA; Graham S; Bernick B; Mirkin S
Menopause; 2020 Nov; 27(11):1236-1241. PubMed ID: 33110039
[TBL] [Abstract][Full Text] [Related]
5. Estradiol and progesterone bioavailability for moderate to severe vasomotor symptom treatment and endometrial protection with the continuous-combined regimen of TX-001HR (oral estradiol and progesterone capsules).
Lobo RA; Liu J; Stanczyk FZ; Constantine GD; Pickar JH; Shadiack AM; Bernick B; Mirkin S
Menopause; 2019 Jul; 26(7):720-727. PubMed ID: 30694918
[TBL] [Abstract][Full Text] [Related]
6. Metabolic and cardiovascular effects of TX-001HR in menopausal women with vasomotor symptoms.
Lobo RA; Kaunitz AM; Santoro N; Bernick B; Graham S; Mirkin S
Climacteric; 2019 Dec; 22(6):610-616. PubMed ID: 31364889
[No Abstract] [Full Text] [Related]
7. Effects of ultra-low dose hormone therapy on biochemical bone turnover markers in postmenopausal women: A randomized, placebo-controlled, double-blind trial.
Costa-Paiva L; O Wender MC; Machado RB; Pompei LM; Nahas EA; Nahas-Neto J; Del Debbio SY; Badalotti M; Cruz AM
Post Reprod Health; 2022 Sep; 28(3):149-157. PubMed ID: 35938207
[TBL] [Abstract][Full Text] [Related]
8. Effects of combined 17β-estradiol and progesterone on weight and blood pressure in postmenopausal women of the REPLENISH trial.
Black DR; Minkin MJ; Graham S; Bernick B; Mirkin S
Menopause; 2020 Sep; 28(1):32-39. PubMed ID: 32932401
[TBL] [Abstract][Full Text] [Related]
9. Relationship between vasomotor symptom improvements and quality of life and sleep outcomes in menopausal women treated with oral, combined 17β-estradiol/progesterone.
Mirkin S; Graham S; Revicki DA; Bender RH; Bernick B; Constantine GD
Menopause; 2019 Jan; 26(6):637-642. PubMed ID: 30601452
[TBL] [Abstract][Full Text] [Related]
10. A combined, bioidentical, oral, 17β-estradiol and progesterone capsule for the treatment of moderate to severe vasomotor symptoms due to menopause.
Archer DF; Bernick BA; Mirkin S
Expert Rev Clin Pharmacol; 2019 Aug; 12(8):729-739. PubMed ID: 31282768
[No Abstract] [Full Text] [Related]
11. A 17β-Estradiol-Progesterone Oral Capsule for Vasomotor Symptoms in Postmenopausal Women: A Randomized Controlled Trial.
Lobo RA; Archer DF; Kagan R; Kaunitz AM; Constantine GD; Pickar JH; Graham S; Bernick B; Mirkin S
Obstet Gynecol; 2018 Jul; 132(1):161-170. PubMed ID: 29889748
[TBL] [Abstract][Full Text] [Related]
12. Breast effects of oral, combined 17β-estradiol, and progesterone capsules in menopausal women: a randomized controlled trial.
Liu JH; Black DR; Larkin L; Graham S; Bernick B; Mirkin S
Menopause; 2020 Dec; 27(12):1388-1395. PubMed ID: 32842052
[TBL] [Abstract][Full Text] [Related]
13. Improvement in sleep outcomes with a 17β-estradiol-progesterone oral capsule (TX-001HR) for postmenopausal women.
Kagan R; Constantine G; Kaunitz AM; Bernick B; Mirkin S
Menopause; 2018 Dec; 26(6):622-628. PubMed ID: 30586005
[TBL] [Abstract][Full Text] [Related]
14. Effects of intranasal 17beta-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women.
Garnero P; Tsouderos Y; Marton I; Pelissier C; Varin C; Delmas PD
J Clin Endocrinol Metab; 1999 Jul; 84(7):2390-7. PubMed ID: 10404809
[TBL] [Abstract][Full Text] [Related]
15. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
Reginster JY; Sarkar S; Zegels B; Henrotin Y; Bruyere O; Agnusdei D; Collette J
Bone; 2004 Feb; 34(2):344-51. PubMed ID: 14962813
[TBL] [Abstract][Full Text] [Related]
16. Reference intervals for serum concentrations of three bone turnover markers for men and women.
Michelsen J; Wallaschofski H; Friedrich N; Spielhagen C; Rettig R; Ittermann T; Nauck M; Hannemann A
Bone; 2013 Dec; 57(2):399-404. PubMed ID: 24076251
[TBL] [Abstract][Full Text] [Related]
17. Reference intervals in Danish children and adolescents for bone turnover markers carboxy-terminal cross-linked telopeptide of type I collagen (β-CTX), pro-collagen type I N-terminal propeptide (PINP), osteocalcin (OC) and bone-specific alkaline phosphatase (bone ALP).
Diemar SS; Lylloff L; Rønne MS; Møllehave LT; Heidemann M; Thuesen BH; Johannesen J; Schou AJ; Husby S; Wedderkopp N; Mølgaard C; Jørgensen NR
Bone; 2021 May; 146():115879. PubMed ID: 33561588
[TBL] [Abstract][Full Text] [Related]
18. Endometrial safety and bleeding profile of a 17β-estradiol/progesterone oral softgel capsule (TX-001HR).
Mirkin S; Goldstein SR; Archer DF; Pickar JH; Graham S; Bernick B
Menopause; 2020 Apr; 27(4):410-417. PubMed ID: 31913228
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of clinical meaningfulness of estrogen plus progesterone oral capsule (TX-001HR) on moderate to severe vasomotor symptoms.
Constantine GD; Revicki DA; Kagan R; Simon JA; Graham S; Bernick B; Mirkin S
Menopause; 2019 May; 26(5):513-519. PubMed ID: 30516713
[TBL] [Abstract][Full Text] [Related]
20. Effects of denosumab on bone turnover markers in postmenopausal osteoporosis.
Eastell R; Christiansen C; Grauer A; Kutilek S; Libanati C; McClung MR; Reid IR; Resch H; Siris E; Uebelhart D; Wang A; Weryha G; Cummings SR
J Bone Miner Res; 2011 Mar; 26(3):530-7. PubMed ID: 20839290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
